PLRX
PLIANT THERAPEUTICS, INC.
Next earnings Aug 5, 2026 · consensus $-0.35 EPS
Last earnings -1.6% on 2026-05-11
$1.14
▲ +0.89%$1.14▼ -8.80%
over 1Y
L $1.09EODHDH $1.87
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+0.9%
1W-1.7%
1M-8.1%
3M-2.6%
YTD-8.8%
1Y-8.8%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 11 analysts
Hold
Conservative balance sheet (liabilities/equity 0.24x).
Revenue (FY2025) $0.00 · FY2025
PLIANT THERAPEUTICS, INC. shows $0.00 in FY2025 revenue, and -82.4% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $7.57M | $9.69M | $1.58M | $0.00 | $0.00 |
| Gross profit | — | — | — | — | — |
| Operating income | -$97.5M | -$127M | -$184M | -$228M | -$156M |
| Net income | -$97.3M | -$123M | -$161M | -$210M | -$149M |
| Diluted EPS | -$2.71 | -$2.94 | -$2.75 | -$3.47 | -$2.43 |
| Net margin | -1284.5% | -1273.3% | -10211.1% | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$25.1M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-211.6%
FCF yield-182.4%
Quality & risk
ROIC (est.)-68.2%
Free cash flow-$129M
Total debt$0.00
Net cash$45.4M
Altman Z-Score-5.71 distress
Piotroski F-Score3/8
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+1.1%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗4Period ending 2026-06-112026-06-12open ↗4Period ending 2026-06-112026-06-12open ↗4Period ending 2026-06-112026-06-12open ↗4Period ending 2026-06-112026-06-12open ↗4Period ending 2026-06-112026-06-12open ↗4Period ending 2026-06-112026-06-12open ↗8-KPeriod ending 2026-06-112026-06-11open ↗10-QPeriod ending 2026-03-312026-05-11open ↗8-KPeriod ending 2026-05-112026-05-11open ↗ARSPeriod ending 2025-12-312026-04-22open ↗DEFA14AFiling2026-04-22open ↗DEF 14APeriod ending 2026-06-112026-04-22open ↗
Frequently asked
- Is PLIANT THERAPEUTICS, INC. (PLRX) a buy?
- PLRX currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.24x).
- What is PLIANT THERAPEUTICS, INC.'s quality score?
- PLRX scores 57.717948717948715/100 (grade C) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001746473, latest 10-Q filed 2026-05-11) · EODHD · as of 6/23/2026, 12:12:29 AM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.